About us

Combatting high cholesterol: Exploring the market trends and opportunities in cholesterol-lowering medications.

The project defines where the client can expand PCV uptake and win procurement contracts. It directs commercial investment toward vaccination programs and population groups where disease burden, funding conditions, and product differentiation create opportunities for growth.

Outcome

  • Validated growth opportunities by patient risk, treatment stage, and therapy class, distinguishing unmet clinical need from commercially accessible demand.
  • Clear positioning for established and newer therapies, reflecting clinical evidence, patient needs, and competition from generic medicines.
  • Defined market access and targeting priorities, addressing reimbursement restrictions, referral barriers, and delays in treatment escalation.
  • Commercial roadmap connecting portfolio choices and prescriber engagement with actions to strengthen treatment initiation and persistence.

KEY INTELLIGENCE OBJECTIVES

  • Estimate market volume and value by therapy class, patient segment and funding channel, assessing the contribution of generic medicines, branded products, and combination therapies.
  • Assess diagnosed and treated populations, including patients with established cardiovascular disease, familial hypercholesterolaemia, and inadequate cholesterol control despite existing treatment.
  • Map treatment pathways across statins, ezetimibe, bempedoic acid, PCSK9 antibodies, and inclisiran, identifying when additional therapies enter care and who determines treatment escalation.
  • Identify why treatment gaps persist, examining reported statin intolerance, adherence challenges, prescribing habits, limited follow-up, and fragmented responsibility between primary and specialist care.
  • Benchmark competing products by positioning, pricing, safety, and administration requirements, distinguishing cholesterol-lowering efficacy from demonstrated cardiovascular outcomes.
  • Examine reimbursement and prescribing restrictions, including eligibility thresholds, prior treatment requirements, and commercial agreements, assessing their implications for accessible demand and pricing.
  • Analyze the roles of primary care physicians, cardiologists, lipid specialists, and pharmacists in product selection, patient education, and continued treatment.
  • Assess how competitor launches, generic availability, combination therapies, and evolving guidelines may reshape demand, competitive pressure, and portfolio priorities.

Geography

  • Europe
  • Middle East
  • Africa
  • North America
  • Latin America
  • Asia-Pacific
  • Global

    • Go back to our case studies

    Get the report

    SUBSCRIBE TO MARKET MINDS

    What matters now. Subscribe to receive intelligence that helps you act before others do.

    Contact us

    Let’s start with a conversation.
    Tell us what you’re facing.

    EMBS GROUP Sp. z o.o. Sp. k., as the Data Administrator, will process the personal data provided above to respond to the message sent via the form. You can contact us at gdpr@embs-group.com or our registered office (Poland, 30-224 Kraków, Aleja Sosnowa 2a).
    The full text of the information clause is available in the Privacy Policy.
    Privacy Overview

    EMBS Group, as the Data Administrator, uses cookies to enhance user experience and analyze website traffic. You can change your cookie settings at any time. For more information, please see our Privacy Policy.